# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT06003231 ‚öîÔ∏è

**Trial Name**: A Study of Disitamab Vedotin in Previously Treated Solid Tum...  
**Patient**: Ayesha Kiani (ID: ayesha_001)  
**Generated**: 2025-11-15T06:50:17.811727  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: GOOD_TIER  
**Composite Score**: 0.72/1.00  
**Eligibility Probability**: ~0%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06003231

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: ACTIVE_NOT_RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: ACTIVE_NOT_RECRUITING
‚úÖ Ovarian cancer trial match
‚úÖ Advanced eligible (patient: IVB)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 11 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~0% (pending biomarkers)

**Semantic Similarity**: 0.815 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~0%  
**Calculation**: P(BRCA+) = 0.00 (patient is BRCA wildtype) ‚Üí NOT ELIGIBLE

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Trial Analysis: NCT06003231**

**Note**: This is a structured fallback analysis (LLM unavailable).

#### **1. Drug Mechanism Fit**
The trial "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2" requires detailed mechanism analysis. Review the trial protocol to understand how the investigational drug addresses Ayesha's Stage IVB High-Grade Serous Ovarian Carcinoma with extensive tumor burden and pleural metastases.

#### **2. Location Logistics**
Review trial locations to identify NYC metro sites accessible from ZIP 10029 (East Harlem). Preferred centers: Mount Sinai (local), MSK (2 miles), NYU Langone (3-4 miles).

#### **3. Risk-Benefit for Ayesha**
**Key Considerations**:
- Pulmonary compromise: Large bilateral pleural effusions require careful monitoring
- ECOG 1: Acceptable for most trials, but toxicity profile is critical
- Tumor burden: Extensive disease (CA-125 >2800) may require aggressive initial treatment

#### **4. Comparison to Standard of Care**
Ayesha's planned SOC is Carboplatin + Paclitaxel + Bevacizumab (NCCN-guideline first-line therapy for Stage IVB HGSOC, BRCA wildtype). This trial should be compared to this regimen to assess:
- Is it a replacement for SOC (frontline trial)?
- Is it additional to SOC (maintenance trial)?
- Is it an alternative if SOC fails?

#### **5. Critical Considerations**
1. **Biomarker testing**: HER2 and HRD status are unknown - may be required for enrollment
2. **Timing**: When should Ayesha enroll? Before SOC, during SOC, or after response?
3. **Clinical team review**: Discuss with Ayesha's oncologist before enrollment decisions

**Recommendation**: Full protocol review with clinical team required.


---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~0%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT06003231

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT06003231
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~0%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
Inclusion Criteria:

* Cohort 1: Head and neck cancer (HNC)

  * Must have pathologically-documented carcinoma of the head and neck with primary tumor site arising from the oral cavity, salivary gland, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded.
  * Unresectable locally recurrent or metastatic stage disease
  * Prior therapies:

    * Participants must have disease progression after treatment with a platinum-based therapy
* Cohort 2: Non-small cell lung cancer (NSCLC)

  * Pathologically documented NSCLC
  * Unresectable locally-advanced or metastatic stage disease
  * Prior therapies

    * Must have progressed during or after a platinum-based therapy for LA/metastatic disease or, within 6 months of platinum-based adjuvant, neoadjuvant, or concomitant chemoradiotherapy for early or locally-advanced stage disease
    * Must have received prior anti-PD(L)1 therapy, unless contraindicated
    * Participants with known AGAs must have received appropriate targeted therapy, where available.
    * No more than 2 prior lines of cytotoxic chemotherapy for advanced disease
* Cohort 3: Ovarian Cancer

  * Pathologically documented epithelial cancers of ovarian, fallopian tube, or peritoneal origin
  * Unresectable locally-advanced or metastatic stage disease
  * Prior therapies

    * Must have platinum resistant disease (6 months or less between the completion of platinum-based treatment and identification of recurrence)
    * Must not have received more than 4 lines of prior cytotoxic chemotherapies for advanced disease
    * Participants with known BRCA mutations are permitted, but participants must have received targeted therapy with a PARP inhibitor
    * May have received prior anti-PD(L)1 therapy
* Cohort 4: Endometrial Cancer

  * Must have pathologically documented adenocarcinoma of the endometrium
  * Must have unresectable locally-advanced or metastatic stage disease.
  * Prior therapies

    * Must have relapsed/progressed after at least one prior platinum-based chemotherapy for recurrent, metastatic or primary unresectable disease
    * Must not have received more than 3 lines of prior cytotoxic chemotherapies for advanced disease
    * May have received prior anti-PD(L)1 therapy
* HER2 expression of 1+, 2+, or 3+, as determined by local IHC testing on a fresh or archival tumor tissue. Note: Participants with HER2 mutations are eligible.
* Measurable disease per RECIST v1.1 criteria as assessed by the investigator
* Able to provide formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides)
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

* Prior treatment with an MMAE-containing agent.
* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin.
* History of another invasive malignancy within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
* Active untreated CNS or leptomeningeal metastasis

---

## üìä TRIAL DESCRIPTION

This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2.

This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks.

This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Smilow Cancer Hospital at Yale - New Haven** - New Haven, Connecticut
2. **Yale-New Haven Hospital-Yale Cancer Center** - New Haven, Connecticut
3. **Smilow Cancer Hospital Phase 1 Unit** - New Haven, Connecticut
4. **Yale Cancer Center** - New Haven, Connecticut
5. **NYU Langone Hospital - Long Island** - Mineola, New York
6. **NYU Langone Hospital-Long Island** - Mineola, New York
7. **Perlmutter Cancer Center at NYU Langone Hospital - Long Island** - Mineola, New York
8. **Laura & Isaac Perlmutter Cancer Center at NYU Langone Health** - New York, New York
9. **Laura & Issac Perlmutter Cancer Center-NYU Ambulatory Care Center(ACC)** - New York, New York
10. **NYU Langone Hospitals** - New York, New York
11. **NYU Langone Medical Center (Tisch Hospital)** - New York, New York

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

### HER2 Testing (Priority: P0 - URGENT)
**Status**: PENDING  
**Test**: HER2 IHC (ASCO-CAP gastric scoring)  
**Turnaround**: 3-5 days  
**Cost**: $200-400  
**Rationale**: HER2 status unknown - testing required. If IHC 1+/2+ (expression, not amplification), Ayesha may be eligible for breakthrough T-DXd trial.


---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: ‚ö†Ô∏è **P1 - HIGH PRIORITY** (Eligibility: ~0%)

**Next Steps**:
1. **Review eligibility carefully** (with oncologist)
2. **Order pending biomarker tests** (if required)
3. **Contact trial site** (within 1 week)
4. **Backup option** (if top-tier trials fail)


---

## üéØ VALUE PROPOSITION

**LOW PROBABILITY SCENARIO**:
- Eligibility: ~0% (low)
- Consider alternative trials with better match
- Keep as backup option

**Risk-Benefit**: Consider higher-probability trials first

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.815  
**Composite Score**: 0.72 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 0.00)  
**LLM Analysis**: Gemini None  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
